Latest Depomed Inc (DEPO) Headlines
PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:
Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)
PR Newswire - Wed Mar 12, 7:45AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's New Drug Application (NDA) for XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. The release profile of XARTEMIS XR combines Mallinckrodt's newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed's advanced Acuform® drug delivery technology.
Depomed To Report Fourth Quarter Fiscal Year 2013 Financial Results On Wednesday, March 12, 2014
PR Newswire - Mon Mar 10, 4:30PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release fourth quarter fiscal year 2013 financial results after the market closes on Wednesday, March 12, 2014. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm Pacific time to discuss its results.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Depomed To Present At The 26th Annual ROTH Conference On Monday, March 10, 2014
PR Newswire - Wed Mar 05, 3:15PM CST
Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the 26th Annual ROTH Conference on Monday, March 10, 2014, at the Ritz Carlton in Dana Point, California.
Depomed, Foot Locker, Oclaro, Mueller Water Products and Magna Intl. Reached New 52-Week High
PR Newswire - Wed Mar 05, 12:40PM CST
Editor Note: For more information about this release, please scroll to bottom.
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sappi Fine Paper North America Announces New Dual Purpose Digital Sheet - Opus® DX
PR Newswire - Tue Mar 04, 7:57AM CST
Sappi Fine Paper North America today launched Opus DX - a cross platform #2 digital cut sheet offering supreme versatility with performance on both dry and liquid toner presses including HP® Indigo, Kodak NexPress, Xerox® iGen3® and Xerox® iGen4®, as well as Canon, Ricoh®, and Konica Minolta bizhub® digital presses. With this launch, the Opus brand just got stronger allowing high-value bundling opportunities across the Opus digital, folio sheet and web lines, perfect for corporate paper programs demanding an optical match in one brand.
3 Stocks Spiking on Unusual Volume
at The Street - Tue Mar 04, 5:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 03, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Depomed Shares Up 113.5% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Mon Mar 03, 9:07AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on July 10th, 2013 at $6.10. In approximately 8 months, Depomed has returned 113.45% as of today's recent price of $13.01.
Saleen Vehicles to be in Front of and Behind the Camera for New DreamWorks Movie, Need for Speed
PR Newswire - Wed Feb 26, 7:15AM CST
Saleen Automotive, Inc. (OTCQB: SLNN), (OTCBB: SLNN) (the "Company"), an American specialty manufacturer of high performance vehicles, technical performance parts, lifestyle accessories and apparel, is pleased to announce that the Company has been asked to provide performance vehicles for DreamWorks Pictures' feature film, Need for Speed.
Depomed Reports Preliminary Q4 2013 and Full Year Financial Information
PR Newswire - Tue Feb 25, 3:05PM CST
Depomed, Inc. (Nasdaq: DEPO) today reported preliminary financial results (unaudited) for the fourth quarter ended December 31, 2013 in anticipation of the company's upcoming presentations and live webcasts at the RBC Global Capital Markets Healthcare Conference and the Cowen & Co. Healthcare Conference.
Depomed To Present At Upcoming Healthcare Conferences
PR Newswire - Thu Feb 20, 1:00PM CST
Depomed, Inc. (NASDAQ EPO) today announced that it will be presenting at the 2014 RBC Capital Markets' Healthcare Conference at The New York Palace Hotel in New York City. The presentation at the RBC conference is scheduled for 2:05 pm EST (11:05 am PST) on Wednesday, February 26, 2014.
Stoneridge To Present At The 29th Annual BB&T Capital Markets Transportation Services Conference
PR Newswire - Tue Feb 11, 7:00AM CST
Stoneridge, Inc. (NYSE: SRI) today announced that John C. Corey, President and Chief Executive Officer, and George E. Strickler, Executive Vice President and Chief Financial Officer, will participate in the 29th Annual BB&T Capital Markets Transportation Services Conference with a Company presentation at 10:10 a.m. Eastern Standard Time on Wednesday, February 12, 2014, at The Biltmore Hotel, located at 1200 Anastasia Avenue, Coral Gables, Florida. The presentation materials will be posted to the "Investors\Webcasts & Presentations" section of the Company's website (www.stoneridge.com) on Tuesday, February 11, 2014.
Depomed Shares Up 98.7% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Fri Feb 07, 10:59AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ EPO) on July 10th, 2013 at $6.10. In approximately 7 months, Depomed has returned 98.69% as of today's recent price of $12.11.
Strength Seen in Furiex Pharmaceuticals (FURX): Stock Shoots 129.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:04AM CST
Furiex Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by nearly 130% on the day.
Depomed Announces Favorable Markman Ruling in GRALISE® Patent Litigation
PR Newswire - Wed Jan 29, 7:00AM CST
Depomed, Inc. (NASDAQ: DEPO) announced today a favorable "Markman" claim construction ruling by Judge Joel A. Pisano of the United States District Court for the District of New Jersey in Depomed's ongoing patent infringement case against filers of three Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of Depomed's GRALISE® (gabapentin) product prior to the expiration of Depomed's patents listed for Gralise in the FDA's Orange Book.
PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:
Depomed Earns $10 Million Milestone for FDA Approval of Mallinckrodt's XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII)
PR Newswire - Wed Mar 12, 7:45AM CDT
Depomed, Inc. (Nasdaq: DEPO) today announced that the U.S. Food and Drug Administration (FDA) approved Mallinckrodt plc's New Drug Application (NDA) for XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. The release profile of XARTEMIS XR combines Mallinckrodt's newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed's advanced Acuform® drug delivery technology.
Depomed To Report Fourth Quarter Fiscal Year 2013 Financial Results On Wednesday, March 12, 2014
PR Newswire - Mon Mar 10, 4:30PM CDT
Depomed, Inc. (NASDAQ: DEPO) today announced that it will release fourth quarter fiscal year 2013 financial results after the market closes on Wednesday, March 12, 2014. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm Pacific time to discuss its results.
Esperion Therapeutics (ESPR) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:21AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Depomed To Present At The 26th Annual ROTH Conference On Monday, March 10, 2014
PR Newswire - Wed Mar 05, 3:15PM CST
Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the 26th Annual ROTH Conference on Monday, March 10, 2014, at the Ritz Carlton in Dana Point, California.
Depomed, Foot Locker, Oclaro, Mueller Water Products and Magna Intl. Reached New 52-Week High
PR Newswire - Wed Mar 05, 12:40PM CST
Editor Note: For more information about this release, please scroll to bottom.
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sappi Fine Paper North America Announces New Dual Purpose Digital Sheet - Opus® DX
PR Newswire - Tue Mar 04, 7:57AM CST
Sappi Fine Paper North America today launched Opus DX - a cross platform #2 digital cut sheet offering supreme versatility with performance on both dry and liquid toner presses including HP® Indigo, Kodak NexPress, Xerox® iGen3® and Xerox® iGen4®, as well as Canon, Ricoh®, and Konica Minolta bizhub® digital presses. With this launch, the Opus brand just got stronger allowing high-value bundling opportunities across the Opus digital, folio sheet and web lines, perfect for corporate paper programs demanding an optical match in one brand.
3 Stocks Spiking on Unusual Volume
at The Street - Tue Mar 04, 5:00AM CST
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 03, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Depomed Shares Up 113.5% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Mon Mar 03, 9:07AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on July 10th, 2013 at $6.10. In approximately 8 months, Depomed has returned 113.45% as of today's recent price of $13.01. Saleen Vehicles to be in Front of and Behind the Camera for New DreamWorks Movie, Need for Speed
PR Newswire - Wed Feb 26, 7:15AM CST
Saleen Automotive, Inc. (OTCQB: SLNN), (OTCBB: SLNN) (the "Company"), an American specialty manufacturer of high performance vehicles, technical performance parts, lifestyle accessories and apparel, is pleased to announce that the Company has been asked to provide performance vehicles for DreamWorks Pictures' feature film, Need for Speed.
Depomed Reports Preliminary Q4 2013 and Full Year Financial Information
PR Newswire - Tue Feb 25, 3:05PM CST
Depomed, Inc. (Nasdaq: DEPO) today reported preliminary financial results (unaudited) for the fourth quarter ended December 31, 2013 in anticipation of the company's upcoming presentations and live webcasts at the RBC Global Capital Markets Healthcare Conference and the Cowen & Co. Healthcare Conference.
Depomed To Present At Upcoming Healthcare Conferences
PR Newswire - Thu Feb 20, 1:00PM CST
Depomed, Inc. (NASDAQ
EPO) today announced that it will be presenting at the 2014 RBC Capital Markets' Healthcare Conference at The New York Palace Hotel in New York City. The presentation at the RBC conference is scheduled for 2:05 pm EST (11:05 am PST) on Wednesday, February 26, 2014. Stoneridge To Present At The 29th Annual BB&T Capital Markets Transportation Services Conference
PR Newswire - Tue Feb 11, 7:00AM CST
Stoneridge, Inc. (NYSE: SRI) today announced that John C. Corey, President and Chief Executive Officer, and George E. Strickler, Executive Vice President and Chief Financial Officer, will participate in the 29th Annual BB&T Capital Markets Transportation Services Conference with a Company presentation at 10:10 a.m. Eastern Standard Time on Wednesday, February 12, 2014, at The Biltmore Hotel, located at 1200 Anastasia Avenue, Coral Gables, Florida. The presentation materials will be posted to the "Investors\Webcasts & Presentations" section of the Company's website (www.stoneridge.com) on Tuesday, February 11, 2014.
Depomed Shares Up 98.7% Since SmarTrend's Buy Recommendation (DEPO)
Comtex SmarTrend(R) - Fri Feb 07, 10:59AM CST
SmarTrend identified an Uptrend for Depomed (NASDAQ
EPO) on July 10th, 2013 at $6.10. In approximately 7 months, Depomed has returned 98.69% as of today's recent price of $12.11. Strength Seen in Furiex Pharmaceuticals (FURX): Stock Shoots 129.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 8:04AM CST
Furiex Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by nearly 130% on the day.
Depomed Announces Favorable Markman Ruling in GRALISE® Patent Litigation
PR Newswire - Wed Jan 29, 7:00AM CST
Depomed, Inc. (NASDAQ: DEPO) announced today a favorable "Markman" claim construction ruling by Judge Joel A. Pisano of the United States District Court for the District of New Jersey in Depomed's ongoing patent infringement case against filers of three Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of Depomed's GRALISE® (gabapentin) product prior to the expiration of Depomed's patents listed for Gralise in the FDA's Orange Book.
